Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ARV
|
|||
| Former ID |
DIB009564
|
|||
| Drug Name |
Anti-IL-23
|
|||
| Synonyms |
Anti-IL-23 (chronic inflammation); Anti-IL-23 (chronic inflammation), Merck & Co; Anti-IL-23 (chronic inflammation), Schering-Plough; Anti-interleukin-23 antibody (chronic inflammation), Merck & Co
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 3 | [1] | |
| Company |
Schering-Plough Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 23 receptor (IL23R) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Inflammatory bowel disease (IBD) | ||||
| Pathway Interaction Database | IL23-mediated signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Merck. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.